title: Cross-priming of cytotoxic T cells dictates antigen requisites for modified vaccinia virus Ankara vector vaccines.
abstract: Recombinant vaccines based on modified vaccinia virus Ankara (MVA) have an excellent record concerning safety and immunogenicity and are currently being evaluated in numerous clinical studies for immunotherapy of infectious diseases and cancer. However, knowledge about the biological properties of target antigens to efficiently induce MVA vaccine-mediated immunity in vivo is sparse. Here, we examined distinct antigen presentation pathways and different antigen formulations contained in MVA vaccines for their capability to induce cytotoxic CD8(+) T-cell (CTL) responses. Strikingly, we found that CTL responses against MVA-produced antigens were dominated by cross-priming in vivo, despite the ability of the virus to efficiently infect professional antigen-presenting cells such as dendritic cells. Moreover, stable mature protein was preferred to preprocessed antigen as the substrate for cross-priming. Our data are essential for improved MVA vaccine design, as they demonstrate the need for optimal adjustment of the target antigen properties to the intrinsic requirements of the delivering vector system.
authors: GSF-Institute for Molecular Virology, Schneckenburgerstrasse 8, D-81675 Munich, Germany.
authors: Georg
authors: G
authors: Gasteiger
authors: Wolfgang
authors: W
authors: Kastenmuller
authors: Ronny
authors: R
authors: Ljapoci
authors: Gerd
authors: G
authors: Sutter
authors: Ingo
authors: I
authors: Drexler
mesh_terms: D000818:Animals; D017951:Antigen Presentation; D045142:Cross-Priming; D003713:Dendritic Cells / Q000378:metabolism / Q000821:virology; D005347:Fibroblasts / Q000378:metabolism; D015395:Histocompatibility Antigens Class I / Q000737:chemistry; D006801:Humans; D007107:Immune System / Q000821:virology; D007167:Immunotherapy / Q000379:methods; D051379:Mice; D008810:Mice, Inbred C57BL; D041681:NIH 3T3 Cells; D013602:T-Lymphocytes, Cytotoxic / Q000821:virology*; D014616:Vaccinia virus / Q000378:metabolism*; D014765:Viral Vaccines / Q000378:metabolism
chemical_list: D015395:Histocompatibility Antigens Class I; D014765:Viral Vaccines
references: Nat Immunol. 2002 Nov;3(11):1019-25
references: 12407410
references: J Virol. 2006 May;80(10):4717-28
references: 16641265
references: J Exp Med. 2003 Apr 7;197(7):927-32
references: 12668642
references: Nat Med. 2003 Jun;9(6):729-35
references: 12766765
references: J Immunol. 2003 Dec 1;171(11):5668-72
references: 14634072
references: Nature. 2004 Jan 8;427(6970):154-9
references: 14712275
references: Immunity. 2004 Jan;20(1):47-58
references: 14738764
references: J Immunol. 2000 Jun 15;164(12):6147-57
references: 10843664
references: Biotechniques. 2000 Jun;28(6):1137-42, 1144-6, 1148
references: 10868279
references: J Exp Med. 2000 Oct 16;192(8):1135-42
references: 11034603
references: J Exp Med. 2000 Oct 16;192(8):1143-50
references: 11034604
references: Int J Cancer. 2000 Nov 1;88(3):432-8
references: 11054673
references: J Exp Med. 2001 Feb 5;193(3):405-11
references: 11157061
references: Eur J Immunol. 2001 Dec;31(12):3432-42
references: 11745362
references: Nat Immunol. 2002 Mar;3(3):265-71
references: 11828323
references: J Immunol. 2002 Jun 1;168(11):5403-8
references: 12023332
references: Immunity. 2002 Aug;17(2):211-20
references: 12196292
references: J Immunol. 2002 Oct 15;169(8):4222-9
references: 12370352
references: Immunity. 2006 May;24(5):643-56
references: 16713981
references: Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3416-24
references: 16740766
references: Virology. 2006 Jul 5;350(2):276-88
references: 16595141
references: Nat Biotechnol. 2006 Jul;24(7):817-9
references: 16767078
references: Immunity. 2006 Jul;25(1):153-62
references: 16860764
references: J Virol. 2006 Sep;80(17):8469-81
references: 16912297
references: Vaccine. 2006 Oct 30;24(42-43):6526-33
references: 16842888
references: Protein Sci. 2007 Jan;16(1):118-24
references: 17123957
references: Vaccine. 2007 Mar 1;25(11):2120-7
references: 17250931
references: Eur J Immunol. 2007 Apr;37(4):954-65
references: 17357104
references: Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):3035-40
references: 14978273
references: Vaccine. 2004 Mar 12;22(9-10):1104-13
references: 15003637
references: Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4590-5
references: 15070762
references: Science. 2004 May 28;304(5675):1314-7
references: 15166378
references: Science. 2004 May 28;304(5675):1318-21
references: 15166379
references: Clin Cancer Res. 2004 Aug 15;10(16):5381-90
references: 15328176
references: J Immunol. 1976 Dec;117(6):2233-8
references: 825578
references: Proc Natl Acad Sci U S A. 1988 Jun;85(11):3830-4
references: 3131764
references: Science. 1994 May 13;264(5161):961-5
references: 7513904
references: J Exp Med. 1996 Feb 1;183(2):527-34
references: 8627164
references: J Virol. 1996 Sep;70(9):6479-85
references: 8709286
references: J Exp Med. 1997 Mar 3;185(5):909-20
references: 9120397
references: Proc Natl Acad Sci U S A. 1997 Apr 1;94(7):3183-8
references: 9096367
references: J Exp Med. 1997 Jun 16;185(12):2043-51
references: 9182675
references: Immunity. 1997 Jun;6(6):715-26
references: 9208844
references: J Virol. 1997 Nov;71(11):8497-503
references: 9343207
references: J Virol. 1998 Feb;72(2):1235-43
references: 9445023
references: Nature. 1998 Mar 5;392(6671):86-9
references: 9510252
references: Virology. 1998 May 10;244(2):365-96
references: 9601507
references: Nature. 1999 Mar 4;398(6722):77-80
references: 10078533
references: J Immunol. 1999 Oct 1;163(7):4058-63
references: 10491010
references: Cancer Res. 1999 Oct 1;59(19):4955-63
references: 10519409
references: Nat Med. 2004 Nov;10(11):1240-4
references: 15502839
references: Curr Opin Biotechnol. 2004 Dec;15(6):506-12
references: 15560976
references: Cancer Immunol Immunother. 2005 May;54(5):453-67
references: 15627214
references: Nat Immunol. 2005 Jun;6(6):593-9
references: 15864309
references: Methods Mol Biol. 2005;301:271-81
references: 15917638
references: PLoS Biol. 2005 Jun;3(6):e185
references: 15839733
references: J Immunol. 2005 Oct 15;175(8):5504-15
references: 16210659
references: Nat Immunol. 2006 Feb;7(2):165-72
references: 16415871
references: Science. 2006 Jan 20;311(5759):377-81
references: 16424340
references: Traffic. 2006 Mar;7(3):308-23
references: 16497225
references: Proc Natl Acad Sci U S A. 2003 Jan 7;100(1):217-22
references: 12518065